Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin. Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune "memory" in glioblastoma animal models
Under terms of the agreement, AbbVie and Gilgamesh Pharmaceuticals have agreed to research and develop a portfolio of next-generation therapeutics for psychiatric disorders.
Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin. Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune "memory" in glioblastoma animal models
The company used their long-standing, certified laboratory partner, Myriad RBM, to conduct protein measurements on blood samples collected from children with Kawasaki disease and is developing commercial options for offering HART KD for children suspected of Kawasaki disease.
Agendia notes this study confirms findings from the STO-3 Trial, previously published in 2017 in JAMA Oncology, and continues to show that the use of MammaPrint to stratify patient populations could help prevent the overtreatment of breast cancer patients.
BioPorto notes it is designed to provide a qualitative result in under 10 minutes from a minimally invasive sample, and to be easily administered at the point of care, the test could provide a much-needed solution to help improve access to viral testing.
Immunexpress notes the first poster, titled "Clinical Performance of a Rapid Sepsis Test on a Near-Patient Molecular Testing Platform," details the clinical validation of SeptiCyte® RAPID. The study compares Immunexpress' rapid version of the SeptiCyte® assay on the Biocartis Idylla™ platform to SeptiCyte® LAB in patients located in the U.S. and Europe.
The aiSLE™ DX Flare Risk Index uses a set of blood-based biomarkers that are measurably altered before the onset of flare symptoms in patients with systemic lupus erythematosus.
This collaboration combines the technological resources of both companies and will apply these to one of the world's largest cohorts of Barrett's esophagus patients with clinical outcome data, including patients who progressed to esophageal cancer.
Aegea Biotechnologies notes XPRIZE is renowned for its worldwide competitions to solve humanity's most important challenges. The $5 million, XPRIZE Rapid COVID Testing competition was launched this summer to accelerate the development of high-quality COVID-19 testing that is affordable, easy to use, and that has a fast turnaround time.
ARUP Laboratories will perform the test only on saliva specimens collected using an ARUP collection kit with a healthcare provider present. ARUP validated the test using its kit on high-throughput instruments, and cannot perform it on other saliva specimens without jeopardizing quick turnaround times, said Adam Barker, Ph.D., director of ARUP's new COVID-19 Rapid Response Lab.
